English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, November 22, 2023
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
Monday, November 20, 2023
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Wednesday, October 25, 2023
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
Monday, October 16, 2023
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
エーザイ、第16回アルツハイマー病臨床試験会議(CTAD)において「レケンビ」の臨床第III相Clarity AD試験の新規データを含むアルツハイマー病領域の最新データを発表
Wednesday, October 11, 2023
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
Wednesday, October 4, 2023
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
Thursday, September 28, 2023
Eisai Launches New "Innovation" Page on Corporate Website
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Monday, September 25, 2023
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575